Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aptorum Group Ltd Class A

Current price
4.5 USD -0.08 USD (-1.75%)
Last closed 4.58 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 24 619 950 USD
Yield for 12 month +59.58 %
21.11.2021 - 28.11.2021

Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections. The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited operates as a subsidiary of Jurchen Investment Corporation. Address: 17 Hanover Square, London, United Kingdom, W1S 1BN

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

80 USD

P/E ratio

Dividend Yield

Current Year

+431 378 USD

Last Year

+1 295 889 USD

Current Quarter

Last Quarter

+431 378 USD

Current Year

-1 114 688 USD

Last Year

+80 065 USD

Current Quarter

-454 606 USD

Last Quarter

-665 333 USD

Key Figures APM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -9 598 997 USD
Operating Margin TTM -2486.04 %
PE Ratio
Return On Assets TTM -32.3 %
PEG Ratio
Return On Equity TTM -37.4 %
Wall Street Target Price 80 USD
Revenue TTM 431 378 USD
Book Value 4.8 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM 81 854 USD
Earnings per share -0.62 USD
Diluted Eps TTM -0.62 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics APM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 23.01.2023
Dividend Date

Stock Valuation APM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 35.5506
Price Sales TTM 35.4572
Enterprise Value EBITDA -2.9826
Price Book MRQ 1.9452

Financials APM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators APM

For 52 weeks

1.35 USD 11.95 USD
50 Day MA 5.36 USD
Shares Short Prior Month 8 603
200 Day MA 3.49 USD
Short Ratio 0.27
Shares Short 5 870
Short Percent 0.32 %

Dynamics of changes in the value of assets




446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds



203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics



2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics